Omixon release SOLiD Alignment plug-in for high-throughput sequencing data analysis Today.
Related StoriesUCPH, Beckman Coulter Genomics recognize ramifications of cancer on proteins signaling networks within individual cellsTwo studies explore potential new blood tests for Alzheimer's diseaseGENALICE announces global release date of new analysis module for genomics researchersCEO of Omixon, Atiila Berces, adds, In every consulting project we found biologically significant variants in significant quantities missed by other NGS evaluation methods and eliminated false positive phone calls. With this collaboration, the benefits of the Omixon software program can reach a lot more scientists.Commercial privileges to ivabradine, an innovative product approved in over 100 countries for heart failure and angina already. In Japan, the Amgen-Astellas strategic alliance began functions on Oct. 1, 2013, and can develop and start five Phase 3 molecules, you start with evolocumab . In China, the jv with Betta Pharma Co. Ltd. In emerging development markets, Amgen repurchased privileges to NEUPOGEN and Neulasta from Roche. Effective Jan. 1, 2014, Amgen will assume responsibility for the products in markets outside the U.S. And European countries with annual sales of around $200 million. About Amgen Amgen is committed to unlocking the potential of biology for sufferers suffering from serious ailments by discovering, developing, manufacturing and providing innovative human therapeutics.